List of Excipients in Branded Drug CAPTOPRIL AND HYDROCHLOROTHIAZIDE

« Back to Dashboard

Generic Drugs Containing CAPTOPRIL AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	captopril and hydrochlorothiazide	0378-0081	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	captopril and hydrochlorothiazide	0378-0081	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	captopril and hydrochlorothiazide	0378-0081	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	captopril and hydrochlorothiazide	0378-0081	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CAPTOPRIL AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
3	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE
3	CROSCARMELLOSE SODIUM

Last updated: August 9, 2026

Captopril/hydrochlorothiazide is an established immediate-release fixed-dose combination with limited patent protection and low regulatory complexity. The strongest commercial opportunities are in low-cost generic supply, chemically robust tablet design, regional distribution, and differentiated packaging rather than new-molecule exclusivity. Excipient selection should prioritize captopril oxidation control, moisture protection, hydrochlorothiazide dissolution, tablet stability, and low-cost manufacturing.

Captopril and Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

What is the commercial status of captopril and hydrochlorothiazide?

Captopril/hydrochlorothiazide combines an angiotensin-converting enzyme inhibitor with a thiazide diuretic. Captopril lowers angiotensin II formation, while hydrochlorothiazide increases renal sodium and water excretion. The combination provides complementary blood-pressure reduction and remains clinically useful where dual therapy is required.

The product is a conventional small-molecule tablet, not a biologic. It does not qualify for biosimilar competition. Generic manufacturers generally use the abbreviated new drug application, or ANDA, pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Commercial attribute	Assessment
Dosage form	Immediate-release oral tablet
Active ingredients	Captopril and hydrochlorothiazide
Primary use	Hypertension
FDA pathway for new generic entrants	ANDA
Biosimilar exposure	None
Original branded product	Capozide
Current exclusivity profile	Historical exclusivity has expired
Main competitive factors	Cost, supply reliability, stability, market access, and wholesaler coverage
Primary formulation risk	Captopril degradation, particularly oxidation and moisture-related instability
Primary development opportunity	Stable, low-cost, globally adaptable fixed-dose tablet

The original product was commercialized by Bristol-Myers Squibb under the Capozide brand. Current market participation is primarily generic and varies by country, wholesaler, reimbursement system, and manufacturing site. Public company filings generally do not report captopril/hydrochlorothiazide revenue separately because the product is usually included within broader generic portfolios.

What excipient problems affect captopril/hydrochlorothiazide tablets?

Captopril is the more sensitive active ingredient. Its sulfhydryl group can oxidize to captopril disulfide. Moisture, oxygen, elevated temperature, and certain formulation environments can accelerate degradation. Captopril also has a strong sulfur-like odor that can affect patient acceptability and packaging requirements.

Hydrochlorothiazide is relatively stable as an active pharmaceutical ingredient but has limited aqueous solubility. Its dissolution performance can be affected by particle size, wetting, tablet porosity, compression force, and excipient selection.

A formulation must therefore balance four objectives:

1. Protect captopril against oxidation and moisture.
2. Maintain hydrochlorothiazide dissolution.
3. Deliver acceptable tablet hardness and friability.
4. Avoid unnecessary excipient complexity that increases cost or regulatory burden.

The commercial formulation target is usually a standard immediate-release tablet rather than a modified-release system. A modified-release design would require additional development, pharmacokinetic justification, and potentially a more difficult regulatory strategy without a clear clinical advantage.

Which excipients are suitable for captopril and hydrochlorothiazide?

Suitable excipients depend on the manufacturing process, target market, and stability data. The following classes are commercially relevant.

Excipient class	Potential function	Strategic considerations
Microcrystalline cellulose	Diluent and dry binder	Supports direct compression and robust tablet formation
Lactose	Diluent	Cost-effective, but compatibility and moisture behavior must be assessed
Mannitol	Diluent and taste-masking aid	Useful where mouthfeel matters, but can increase cost
Dibasic calcium phosphate	Diluent	Improves compaction but may alter dissolution and process behavior
Povidone	Binder	Useful in wet granulation; residual moisture must be controlled
Copovidone	Binder	Supports granulation and compression in some platforms
Crospovidone	Superdisintegrant	Often suitable for rapid breakup of immediate-release tablets
Croscarmellose sodium	Superdisintegrant	Effective at low levels, subject to compression and moisture effects
Sodium starch glycolate	Superdisintegrant	Can improve disintegration but may be sensitive to over-compression
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow; excessive use can affect compaction
Magnesium stearate	Lubricant	Over-lubrication can reduce tablet hardness and dissolution
Stearic acid	Lubricant	Alternative lubricant with different process behavior
Sodium metabisulfite or related antioxidant systems	Oxidation control	Requires compatibility, toxicology, and regulatory assessment
Film-coating polymers	Appearance and protection	Can reduce moisture and odor exposure but adds process cost
Opacifiers and pigments	Light protection and identification	Useful for product differentiation and stability control

Antioxidants require particular caution. A reducing excipient may slow captopril oxidation, but the choice must be supported by impurity, stability, and compatibility data. The excipient cannot be selected solely from precedent in unrelated products. It must be evaluated against the complete formulation, packaging system, granulation process, and expected storage conditions.

A low-risk starting platform is a dry-blended or direct-compression tablet using a stable diluent system, a superdisintegrant, a controlled lubricant level, and a protective film coat. Wet granulation can improve content uniformity and flow, but it introduces water and drying steps that may increase captopril degradation risk.

How should the formulation protect captopril from oxidation?

The most important controls are formulation, process, and packaging. No single excipient is likely to replace a complete stability strategy.

Formulation controls

The formulation should minimize sources of reactive moisture and oxygen. Key development variables include:

• Water activity of incoming excipients.
• Residual moisture after granulation or coating.
• Exposure time to ambient humidity.
• Use of antioxidant or oxygen-control excipients.
• Lubrication time and blend uniformity.
• Tablet porosity and coating integrity.
• Captopril disulfide formation during accelerated stability testing.

The development program should monitor captopril assay, captopril disulfide, hydrochlorothiazide assay, dissolution, water content, hardness, friability, and appearance. The impurity profile should be tracked under long-term and accelerated conditions.

Process controls

Direct compression minimizes water exposure but requires highly consistent powder flow and content uniformity. Dry granulation can improve flow while avoiding liquid water. Wet granulation may be acceptable if the process uses controlled moisture exposure, rapid drying, low residual water, and validated hold times.

A manufacturing process should limit open handling after active blending. Nitrogen flushing or low-oxygen processing can be considered for high-risk platforms, although these controls may be unnecessary if the formulation and packaging provide sufficient stability.

Packaging controls

Packaging is a major commercial lever. Options include:

• High-barrier PVC/PVdC or PCTFE blister systems.
• Aluminum-aluminum blisters for high moisture protection.
• High-density polyethylene bottles with induction seals.
• Desiccant-containing bottles.
• Light-protective containers.
• Unit-dose packaging for institutional and adherence markets.

A low-cost bottle may be adequate in a dry climate but fail in hot, humid markets. Regional packaging specifications should be based on ICH climatic-zone stability data rather than on the lowest packaging cost alone. The formulation and package should be developed as one product system.

What formulations are protected or differentiated in the market?

Historical product patents and brand exclusivity for captopril/hydrochlorothiazide have expired. The combination is generally viewed as an off-patent immediate-release product. The remaining commercial differentiation is more likely to arise from formulation know-how, process control, packaging, supply reliability, and regulatory execution than from blocking composition-of-matter rights.

Potentially differentiating formulation concepts include:

Low-moisture direct-compression tablets

This platform reduces water exposure and can support a short manufacturing process. It is commercially attractive where the active ingredients have acceptable flow and content-uniformity performance.

Dry-granulated tablets

Roller compaction can improve flow and compressibility without introducing liquid water. The main risks are fines generation, segregation, ribbon-density variation, and potential dissolution changes.

Odor-controlled film-coated tablets

A film coat can reduce sulfur-like odor and improve appearance. The coating must not create a dissolution delay or introduce excessive moisture during processing.

High-barrier unit-dose packaging

This approach can improve stability in institutional settings and humid markets. Its disadvantages are higher packaging cost, slower packaging throughput, and potential reimbursement pressure.

Strength-specific formulation platforms

Commercial products may use multiple strengths, such as 25 mg/15 mg, 25 mg/25 mg, and 50 mg/25 mg captopril/hydrochlorothiazide tablets. A common formulation platform across strengths can lower development and manufacturing costs, but the lowest-dose strength may present greater content-uniformity challenges.

What is the FDA regulatory status of captopril/hydrochlorothiazide?

The product is regulated as a conventional oral drug. A new generic product normally requires an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the designated reference listed drug.

The principal regulatory requirements include:

• Same active ingredients as the reference product.
• Same dosage form and route of administration.
• Equivalent strength.
• Pharmaceutical equivalence.
• Bioequivalence under FDA requirements.
• Compliance with current good manufacturing practice.
• Adequate stability data.
• Validated analytical methods.
• Appropriate labeling and inactive-ingredient disclosure.

FDA’s Orange Book identifies reference listed drugs, therapeutic equivalence evaluations, patents, and exclusivity information. Because generic availability and Orange Book records can change, commercial diligence should rely on the current FDA Orange Book and Drugs@FDA entries for the intended strength and dosage form.[1,2]

For an immediate-release tablet, the principal technical burden is usually analytical and manufacturing control rather than complex clinical development. The sponsor must still demonstrate that the product does not show clinically meaningful differences in absorption compared with the reference product.

What is the Orange Book and patent status of captopril/hydrochlorothiazide?

The original captopril and hydrochlorothiazide patent estates are old. Composition-of-matter protection for both active ingredients has expired, and the historic branded fixed-dose combination is outside its original exclusivity period.

The practical patent position is:

Issue	Commercial assessment
Captopril composition-of-matter patent	Expired
Hydrochlorothiazide composition-of-matter patent	Expired
Original combination-product exclusivity	Expired
New generic composition patents	Unlikely to create broad market barriers
Formulation patents	Possible in principle, but typically narrow and product-specific
Method-of-use patents	Limited commercial blocking value for established hypertension use
Orange Book relevance	Must be checked by strength and reference product
Freedom-to-operate focus	Manufacturing process, formulation, packaging, trademarks, and country-specific rights

A company should not assume that an expired active-ingredient patent eliminates every legal issue. It should screen for later formulation patents, process patents, trademarks, regulatory exclusivities, and country-specific rights. For a conventional generic entrant, however, the risk of a broad blocking patent is generally low compared with protected branded products.

Which companies are challenging captopril/hydrochlorothiazide patents?

The commercial market is primarily a generic market rather than a patent-challenge market. Paragraph IV litigation is less likely to drive value because the historical patents for the active ingredients and original combination have expired.

Potential entrants are more likely to file standard ANDAs or national generic applications without relying on a high-value Paragraph IV strategy. The competitive field typically includes:

• Large multinational generic companies.
• Regional manufacturers with hypertension portfolios.
• Contract development and manufacturing organizations.
• Government-tender suppliers.
• Local companies seeking national registrations.

A Paragraph IV certification could still arise against a later-listed formulation patent, but the economic significance would depend on the patent scope, remaining term, market size, and whether the patent covers the reference product or only a narrow formulation feature.

What generic launch risks exist for captopril/hydrochlorothiazide?

Generic launch risk is primarily operational and commercial.

Regulatory risk

The principal risks are failure to demonstrate bioequivalence, analytical method deficiencies, inadequate impurity control, dissolution differences, and incomplete stability data. Captopril disulfide control is likely to receive close scrutiny because it is a known degradation pathway.

Manufacturing risk

Potential manufacturing problems include:

• Segregation caused by different active-ingredient loadings.
• Poor flow at low hydrochlorothiazide concentration.
• Over-lubrication and slow dissolution.
• Moisture uptake during granulation or coating.
• Odor complaints.
• Batch-to-batch impurity variation.
• Packaging failures in humid climates.

Commercial risk

The product may have limited margin because:

• Several generic suppliers may already exist.
• Hypertension tenders favor low price.
• Physicians increasingly use newer fixed-dose combinations.
• Some markets have shifted toward once-daily therapies.
• The product may be absent from major formularies.
• Low sales volumes can make multiple strengths uneconomic.

A launch is more attractive when the manufacturer has an existing cardiovascular sales channel, established tablet capacity, and access to regulated or tender markets.

How strong is the patent estate for captopril/hydrochlorothiazide?

The patent estate is weak as a barrier to conventional generic entry. The value lies in execution rather than exclusivity.

Patent dimension	Strength
Active-ingredient protection	Very low
Original combination protection	Very low
Standard immediate-release tablet protection	Low
Novel excipient system	Potentially moderate, but narrow
Manufacturing process protection	Potentially moderate
Packaging-related protection	Usually low to moderate
Method-of-use protection for hypertension	Low
Biosimilar protection	Not applicable

A novel formulation patent would need meaningful technical differentiation, such as improved stability, dissolution, odor control, or bioavailability. A patent claiming routine excipient substitutions may face validity and obviousness challenges.

What commercial opportunities exist in the captopril/hydrochlorothiazide market?

Low-cost generic supply

The clearest opportunity is a reliable, low-cost product using a simple manufacturing process and economical packaging. Margin depends on procurement costs, production scale, market access, and the number of registered competitors.

Humid-climate markets

Moisture-protective packaging and validated stability in hot, humid regions can create a competitive advantage. Many suppliers optimize for low packaging cost and may have weaker performance under demanding climatic conditions.

Institutional and tender supply

Hospitals and public-health systems may purchase fixed-dose antihypertensive combinations through tenders. Success depends on price, registration status, local manufacturing requirements, delivery performance, and shelf life.

Portfolio bundling

A company selling captopril, hydrochlorothiazide, other antihypertensives, and cardiovascular medicines can use the combination to expand formulary coverage. The product has greater strategic value as part of a portfolio than as a standalone premium product.

Contract manufacturing

The formulation is suitable for CDMO development if the manufacturer has validated immediate-release tablet capacity and strong impurity-control systems. A standardized platform can support multiple strengths and markets.

Packaging differentiation

Calendar blisters, unit-dose packs, and high-barrier packaging may support adherence and institutional use. The commercial return depends on whether payers recognize the benefit and whether packaging costs remain acceptable.

How does captopril/hydrochlorothiazide compare with newer antihypertensive combinations?

Captopril/hydrochlorothiazide has a lower innovation profile than combinations based on angiotensin receptor blockers, calcium-channel blockers, or newer once-daily products.

Product characteristic	Captopril/HCTZ	Newer fixed-dose combinations
Patent barrier	Low	Often moderate to high
Dosing frequency	Commonly multiple daily doses for captopril	Often once daily
Manufacturing complexity	Low to moderate	Variable
Generic price pressure	High	Lower before patent expiry
Clinical familiarity	Established	Strong for newer guideline-preferred products
Differentiation potential	Packaging and stability	Delivery system, dosing, and clinical positioning
Biosimilar relevance	None	None for small molecules

Captopril has a shorter duration of action than many newer renin-angiotensin system agents. That characteristic can limit premium commercial positioning, but it also supports use where low-cost, familiar treatment is prioritized.

What licensing deals affect this product?

Major licensing value is unlikely for the active ingredients because they are long off patent. Licensing opportunities are more likely to involve:

• Regional distribution rights.
• Local manufacturing and technology transfer.
• Government-tender partnerships.
• Contract manufacturing.
• Registration dossiers.
• Brand or trademark rights in specific countries.
• Proprietary packaging or stability technology.

A licensing transaction should be evaluated on the basis of remaining market size, registration status, supply obligations, manufacturing transfer costs, and territorial competition. A conventional product license is unlikely to justify a substantial upfront payment unless it includes broad regional access or a protected distribution channel.

Key Takeaways

• Captopril/hydrochlorothiazide is an established, off-patent fixed-dose antihypertensive tablet.
• Captopril oxidation and moisture exposure are the central formulation risks.
• Direct compression or dry granulation is generally more attractive than water-intensive processing.
• Antioxidant selection requires compatibility and impurity data, not only precedent.
• High-barrier packaging can improve performance in humid markets.
• FDA generic entry normally proceeds through the ANDA pathway.
• Biosimilar competition is irrelevant because both active ingredients are small molecules.
• Paragraph IV litigation is unlikely to be the main commercial issue unless a later formulation patent is listed.
• The strongest opportunities are low-cost supply, regional registration, institutional tenders, portfolio bundling, and stability-focused packaging.
• Patent strength is low; manufacturing discipline, regulatory execution, and distribution determine commercial value.

Frequently Asked Questions

Is captopril/hydrochlorothiazide still protected by patents?

The original active-ingredient and combination-product patent protections have expired. Later formulation or process patents must be reviewed separately by jurisdiction and product strength.

What is the main degradation impurity in captopril tablets?

Captopril disulfide is the principal degradation concern associated with oxidation of captopril’s sulfhydryl group.

Can captopril/hydrochlorothiazide be developed as a generic without a clinical efficacy trial?

A conventional generic normally uses the ANDA pathway and relies on pharmaceutical equivalence and bioequivalence rather than repeating full efficacy trials.

Is hydrochlorothiazide difficult to formulate with captopril?

The combination is technically feasible, but hydrochlorothiazide’s limited solubility and captopril’s oxidation sensitivity require control of particle size, disintegration, dissolution, moisture, and impurity formation.

Which packaging is strongest for humid climates?

Aluminum-aluminum blisters generally provide stronger moisture protection than standard low-barrier blister films. High-density polyethylene bottles with appropriate seals and desiccants can also be suitable when supported by stability data.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

3. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products. FDA.

4. U.S. Food and Drug Administration. (2015). Q1A(R2) stability testing of new drug substances and products. FDA.

5. DailyMed. (2024). Captopril and hydrochlorothiazide tablet labeling. National Library of Medicine.

6. International Council for Harmonisation. (2023). Q8(R2): Pharmaceutical development. ICH.

7. International Council for Harmonisation. (2023). Q9(R1): Quality risk management. ICH.

8. International Council for Harmonisation. (2023). Q10: Pharmaceutical quality system. ICH.